Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63723283 plus daratumumab versus daratumumab alone in relapsed or refractory multiple myeloma
MOH_2017-11-15_000805Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Daratumumab alone with JNJ-63723283 + daratumumab (2 arms). Primary endpoints: Safety of JNJ-63723283 plus daratumumab, Overall response rate and 1 more. Started Nov 2017; status: completed.
02
Drugs
cetrelimabdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-11-15_000805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-15_000805.